Search

Search Results

• Treatment of Chronic Myeloid Leukemia According to Current Guidelines: The Results of the Pilot Prospective Study “Early Induction Therapy and Monitoring” (РИТМ)

  Oleg Aleksandrovich Shukhov, A.G. Turkina, E.Yu. Chelysheva, A.V. Bykova, A.N. Petrova, G.A. Gusarova, I.S. Nemchenko, A.O. Abdullaev, T.N. Obukhova, A.B. Sudarikov

  194-201

  01.04.2019

• Clinical Experience and Perspectives of Bosutinib Use in Patients with Chronic Myeloid Leukemia

  V.A. Shuvaev, Ol’ga Yur’evna Vinogradova, I.S. Martynkevich, N.V. Novitskaya, M.S. Fominykh, S.N. Tsareva, D.I. Shikhbabaeva, M.M. Pankrashkina, M.V. Chernikov, N.N. Sharkunov, I.I. Zotova, V.Yu. Udal’eva, E.V. Motyko, S.V. Voloshin

  288-294

  01.10.2018

• Cardiovascular Toxicity of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia

  I.L. Davydkin, Kseniya Viktorovna Naumova, A.M. Osadchuk, I.A. Zolotovskaya, O.E. Danilova, T.Yu. Stepanova, O.V. Tereshina, L.V. Limareva, A.S. Shpigel’, T.P. Kuz’mina

  378-387

  01.10.2018

• The Use of Pomalidomide in the Treatment of Relapsed/Refractory Multiple Myeloma in Patients with Renal Failure

  Irina Germanovna Rekhtina, M.V. Nareiko, L.P. Mendeleeva

  283-287

  01.10.2018

• Dermatological Toxicity of Hydroxycarbamide

  Irina Nikolaevna Subortseva, A.L. Melikyan, E.A. Gilyazitdinova, T.I. Kolosheinova, E.I. Pustovaya, E.K. Egorova, A.M. Kovrigina, A.B. Sudarikov, A.O. Abdullaev

  252-258

  01.07.2018

• Current Opportunities for Treatment Optimization of Mycosis Fungoides and Sezary Syndrome

  Natal’ya Gennad’evna Chernova, O.A. Kolomeitsev

  34-41

  01.01.2018

• Ibrutinib in the Treatment of Relapsed Chronic Lymphocytic Leukemia

  Elena Aleksandrovna Stadnik, N.S. Timofeeva, V.V. Strugov, A.Yu. Zaritskey

  42-49

  01.01.2018

• Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia

  Evgenii Aleksandrovich Nikitin, E.A. Dmitrieva, M.A. Panteleev, E.I. Emelina, V.L. Ivanova, Yu.B. Kochkareva, E.G. Arshanskaya, I.E. Lazarev, E.E. Markova, L.A. Mukha, N.G. Novitskaya, M.M. Pankrashkina, V.V. Glazunova, A.V. Shubina, S.A. Chernysh, N.K. Khuazheva, E.V. Naumova, S.A. Lugovskaya, M.E. Pochtar’, T.N. Obukhova, O.Yu. Vinogradova, G.E. Gendlin, V.V. Ptushkin

  271-281

  01.07.2017

• Pomalidomide in Combination with Low-Dose Dexamethasone as the Treatment of “Double Refractory” Multiple Myeloma

  Aleksei Vladilenovich Petrov, D.V. Motorin, O.S. Pokrovskaya, E.S. Urnova, M.V. Nareiko, D.V. Babenetskaya, Yu.A. Alekseeva, L.L. Girshova, L.P. Mendeleeva, A.Yu. Zaritskii

  372-380

  01.07.2017

• Clinical Recommendations for the Diagnosis and Treatment of Chronic Myeloid Leukemia

  Anna Grigor’evna Turkina, A.Yu. Zaritskii, V.A. Shuvaev, E.Yu. Chelysheva, E.G. Lomaia, E.V. Morozova, A.K. Golenkov, T.I. Pospelova, O.A. Shukhov, M.S. Fominykh, G.A. Gusarova, L.A. Kuz’mina, A.O. Abdullaev, I.S. Martynkevich

  294-316

  01.07.2017

• Thrombopoietin Receptor Agonists in Treatment of Idiopathic Thrompocytopenic Purpura (Primary Immune Thrombocytopenia): Efficacy and Safety in Everyday Clinical Practice

  Irina Ivanovna Zotova, S.V. Gritsaev, E.R. Shilova, N.A. Potikhonova, K.М. Abdulkadyrov, A.V. Chechetkin

  93-100

  01.01.2017

• Arterial Events in Patients with Chronic Myeloid Leukemia Receiving Treatment with Second Generation Tyrosine Kinase Inhibitors

  Galina Anatol’evna Gusarova, A.G. Turkina

  474-484

  01.10.2016

• Chronic Myeloid Leukemia: Long-Term Experience of Target Therapy

  K.M. Abdulkadyrov, Vasilii Anatol’evich Shuvaev, I.S. Martynkevich, M.S. Fominykh, N.A. Potikhonova, I.I. Zotova, V.Yu. Udal’eva, R.A. Golovchenko, N.V. Shakhvorostova, D.I. Shikhbabaeva, M.N. Zenina, S.A. Tiranova, S.A. Kudryashova, L.S. Martynenko, M.P. Ivanova, N.Yu. Tsybakova, E.V. Petrova, L.B. Polushkina, E.V. Kleina

  54-60

  01.01.2016

• Multiple Myeloma: 7-Year Experience of Applying Targeted Therapy in Novosibirsk and Its Results

  T.I. Pospelova, Nataliya Valer’evna Skvortsova, I.N. Nechunaeva

  267-273

  01.07.2015

• Rationale for Maintenance Treatment of Patients with Acute Myeloid Leukemia below 65 Years of Age, According to Data of a Retrospective Analysis of Protocols AML-2000 and AML-2007

  S.V. Semochkin, T.N. Tolstykh, V.V. Lunin, N.K. Khuazheva, A.I. Kostin, S.A. Chernysh, M.E. Pochtar, V.L. Ivanova

  564-572

  01.10.2014

• Imatinib Generics: Myths and Reality (Literature Review and Our Experience)

  K.M. Abdulkadyrov, V.A. Shuvaev, M.S. Fominykh

  311-316

  01.07.2014

• Genfatinib® therapy for chronic-phase chronic myeloid leukemia in routine clinical practice

  T.V. Chagorova, V.V. Yablokova, P.A. Borkina, N.A. Pryanikova

  434-438

  01.10.2013